Skip to content
10-Q

Quarterly Report

Adaptive Biotechnologies Corp ADPT

0000950170-25-061897

← back to feed
Filed
May 1, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 24, 2025 151.92M sh
Long Term Debt Q1 2025 · Mar 31, 2025 $131.55M
Long Term Debt Q1 2025 · Dec 31, 2024 $132.41M
Short Term Debt Q1 2025 · Mar 31, 2025 $2.01M
Short Term Debt Q1 2025 · Dec 31, 2024 $865K
Stockholders Equity Q1 2025 · Mar 31, 2025 $190.42M
Stockholders Equity Q1 2025 · Dec 31, 2024 $202.71M
Current Liabilities Q1 2025 · Mar 31, 2025 $87.81M
Current Liabilities Q1 2025 · Dec 31, 2024 $98.05M
Total Liabilities Q1 2025 · Mar 31, 2025 $320.63M
Total Liabilities Q1 2025 · Dec 31, 2024 $336.89M
Current Assets Q1 2025 · Mar 31, 2025 $256.49M
Current Assets Q1 2025 · Dec 31, 2024 $283.75M
Total Assets Q1 2025 · Mar 31, 2025 $510.85M
Total Assets Q1 2025 · Dec 31, 2024 $539.38M
Cash And Equivalents Q1 2025 · Dec 31, 2024 $47.92M
Shares Diluted Q1 2025 · Mar 31, 2024 145.79M sh
Capex Q1 2025 · Mar 31, 2024 $1.51M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −$38.35M
Eps Diluted Q1 2025 · Mar 31, 2024 −$0.33
Eps Basic Q1 2025 · Mar 31, 2024 −$0.33
Sga Expense Q1 2025 · Mar 31, 2024 $19.6M
Rd Expense Q1 2025 · Mar 31, 2024 $30.25M
Net Income Q1 2025 · Mar 31, 2024 −$47.51M
Operating Income Q1 2025 · Mar 31, 2024 −$48.76M
Cost Of Revenue Q1 2025 · Mar 31, 2024 $18.05M
Revenue Q1 2025 · Mar 31, 2024 $41.87M